The IAH1 knockout Jurkat polyclonal cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the IAH1 gene has been disrupted within the Jurkat T-lymphocyte cell line. This heterogeneous pool of edited cells allows loss-of-function studies without single-cell cloning, maintaining the inherent variability of the host line. The targeted gene disruption was achieved using the CRISPR/Cas9 system, making these cells suitable for functional genomic screens and detailed investigation of IAH1 in T-cell biology.
The Jurkat cell line, originally derived from the peripheral blood of a 14-year-old male with acute T-cell leukemia, is an immortalized T lymphocyte widely employed for examining T-cell signaling, activation, and apoptosis. Its well-characterized signaling networks, including TCR-mediated pathways, and its susceptibility to genetic manipulation establish it as a robust platform for gene editing. Disruption of IAH1 in this leukemic background enables the study of esterase function within a relevant T-cell model.
IAH1 encodes a putative esterase with predicted activity toward isoamyl acetate and similar ester substrates, suggesting a role in intracellular lipid metabolism. By hydrolyzing ester bonds, IAH1 may modulate the composition of lipid pools and influence the availability of lipid second messengers. Although its upstream regulators are not well defined, IAH1 expression might respond to metabolic stress or transcriptional programs that sense lipid status. Downstream targets and interacting protein partners remain unknown, but IAH1 likely contributes to cellular ester turnover and lipid droplet dynamics. In Jurkat cells, knockout of IAH1 could disrupt lipid-dependent signaling cascades that are critical for lymphocyte function.
Given the central role of Jurkat cells in T-cell research, the IAH1 knockout model provides a tool to probe the intersection between lipid metabolism and leukemic T-cell biology. Loss of IAH1 esterase activity may alter processes such as T-cell activation, proliferation, or apoptosis through changes in lipid-derived signaling molecules. As lipid dysregulation is a hallmark of many cancers, this polyclonal population allows researchers to examine how a specific esterase deficiency affects leukemic cell behavior and metabolic adaptation, potentially revealing novel therapeutic targets.
These polyclonal knockout cells are applicable in diverse assays, including Western blotting and RT?qPCR for confirming IAH1 disruption, esterase activity measurements with isoamyl acetate substrate, lipidomics to assess global lipid changes, MTT?based proliferation assays, flow cytometric detection of activation markers (CD69, CD25) and apoptosis (Annexin V), and phospho?signaling analysis of ERK and AKT. They support functional genomics, drug screening, and mechanistic investigations in T-cell leukemia. For further inquiries, please contact Ascent Research.
